3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis
Key Takeaways
- Human placental lactogen is the primary mediator of maternal insulin resistance, and normal pregnancy requires a 200 to 300 percent increase in insulin production to maintain euglycemia.
- Glucose crosses the placenta by facilitated diffusion through GLUT-1 but maternal insulin does not, so fetal hyperinsulinemia is the mechanism of macrosomia and neonatal hypoglycemia.
- A 50 g glucose challenge result of 200 mg/dL or higher diagnoses gestational diabetes without proceeding to the 3-hour test.
- Carpenter-Coustan thresholds on the 100 g 3-hour test are fasting 95, 1-hour 180, 2-hour 155, and 3-hour 140 mg/dL, with two or more abnormal values required for diagnosis.
- The one-step 75 g IADPSG protocol uses fasting 92, 1-hour 180, and 2-hour 153 mg/dL, and any single abnormal value is diagnostic, raising detection to roughly 15 to 20 percent versus 6 to 9 percent.
Pregnancy is a state of engineered insulin resistance, and gestational diabetes is what happens when maternal beta-cell reserve cannot keep pace with it. Understanding which placental hormones drive that resistance, and when they peak, explains both the timing of universal screening and the neonatal consequences of missing the diagnosis.
Gestational Diabetes Mellitus (GDM): Pathophysiology & Fetal Consequences
Placental Diabetogenic Hormones
Pregnancy is characterized by progressive physiologic insulin resistance. This adaptation ensures an abundant, continuous flux of glucose across the placenta to meet the energetic demands of the rapidly growing fetus.
Starting in the second trimester, the syncytiotrophoblast secretes increasing quantities of counter-regulatory hormones:
- Human Placental Lactogen (hPL): Also known as human chorionic somatomammotropin (hCS), hPL is the primary mediator of maternal insulin resistance. It impairs insulin-stimulated peripheral glucose uptake in skeletal muscle and adipose tissue while promoting maternal lipolysis.
- Progesterone & Estrogen: Inhibit peripheral insulin receptor sensitivity and downregulate insulin receptor substrate-1 (IRS-1) signaling.
- Placental Growth Hormone (PGH): Modifies maternal insulin sensitivity and hepatic gluconeogenesis.
- Cortisol and Prolactin: Further stimulate hepatic glucose production and suppress insulin efficiency.
- Tumor Necrosis Factor-alpha (TNF-α): A placental cytokine that directly correlates with insulin resistance in late gestation.
In normal pregnancy, maternal pancreatic beta cells undergo hyperplasia and hypertrophy, increasing insulin production by 200% to 300% to maintain maternal euglycemia. Gestational diabetes mellitus develops when maternal pancreatic beta-cell reserve is inadequate to overcome this pregnancy-induced peripheral insulin resistance.
The Pedersen Hypothesis & Neonatal Sequelae
Glucose crosses the placenta readily via facilitated diffusion using glucose transporter 1 (GLUT-1), whereas maternal insulin does not cross the placenta.
- Maternal Hyperglycemia: Leads to persistent fetal hyperglycemia.
- Fetal Hyperinsulinemia: By 12 to 14 weeks gestation, the fetal pancreas responds to excessive glucose loads by secreting large amounts of endogenous insulin and insulin-like growth factors (IGF-1).
- Accelerated Growth (Macrosomia): Insulin functions as a potent fetal growth hormone, stimulating lipogenesis, glycogen synthesis, and protein accretion. Fetal fat preferentially accumulates in the shoulders and abdominal circumference, resulting in asymmetric macrosomia and a marked risk of shoulder dystocia.
- Organomegaly & Cardiac Septal Hypertrophy: Fetal hyperinsulinemia triggers cellular hyperplasia in the liver, spleen, and heart. Subaortic asymmetric septal hypertrophy can lead to transient left ventricular outflow obstruction in the neonate.
- Neonatal Hypoglycemia: At birth, the maternal glucose supply is abruptly severed upon cord clamping, but neonatal hyperinsulinemia persists, driving glucose into tissues and causing profound hypoglycemia within the first 1 to 4 hours of life.
- Polycythemia and Hyperbilirubinemia: Increased fetal metabolic rate and oxygen consumption induce relative fetal tissue hypoxia, stimulating erythropoietin production. Neonatal polycythemia (hematocrit >65%) increases blood viscosity and, upon red blood cell breakdown, yields hyperbilirubinemia.
- Respiratory Distress Syndrome (RDS): Hyperinsulinemia inhibits the synthesis of surfactant proteins (specifically surfactant protein A and B) and lecithin, delaying pulmonary maturation even in late-preterm and early-term infants.
Screening and Diagnostic Strategies for GDM
Universal vs. Early Screening
- Universal Screening: Conducted for all pregnant individuals between 24 0/7 and 28 6/7 weeks gestation, when placental hormone concentrations rise steeply.
- Early Screening (1st Trimester or Initial Prenatal Visit): Recommended for individuals with substantial risk factors: pre-pregnancy BMI ≥30 kg/m², prior GDM, known impaired glucose metabolism (HbA1c 5.7%–6.4%), first-degree relative with Type 2 diabetes, polycystic ovary syndrome (PCOS), or history of delivering a macrosomic infant (≥4,000–4,500 g). Diagnostic criteria in early pregnancy evaluate for undiagnosed pregestational diabetes (e.g., fasting glucose ≥126 mg/dL or HbA1c ≥6.5%).
Screening Protocols: Two-Step vs. One-Step Approaches
[ GDM SCREENING PROTOCOLS ]
│
┌───────────────────────────┴───────────────────────────┐
▼ ▼
[ TWO-STEP APPROACH (ACOG) ] [ ONE-STEP APPROACH (ADA/IADPSG) ]
Step 1: 50g Non-Fasting GLT Fasting 75g 2-Hour OGTT
Thresholds: ≥135 or ≥140 mg/dL Fasting: ≥92 mg/dL
If ≥200 mg/dL: GDM Diagnosed 1-Hour: ≥180 mg/dL
│ 2-Hour: ≥153 mg/dL
If 135–199 mg/dL: Proceed to Step 2 │
▼ ANY SINGLE abnormal value
Step 2: 100g Fasting 3-Hour OGTT confirms GDM diagnosis
Carpenter-Coustan Thresholds:
• Fasting: ≥95 mg/dL
• 1-Hour: ≥180 mg/dL
• 2-Hour: ≥155 mg/dL
• 3-Hour: ≥140 mg/dL
│
≥2 abnormal values confirm GDM
| Feature | Two-Step Approach (ACOG Standard) | One-Step Approach (IADPSG / ADA) |
|---|---|---|
| Initial Test | 50-gram oral Glucose Challenge Test (GLT) | None; proceeds directly to diagnostic test |
| Patient Preparation | Non-fasting, arbitrary time of day | Strict overnight fast of at least 8 hours |
| Screening Threshold | Plasma glucose ≥135 or ≥140 mg/dL at 1 hour | N/A |
| Direct Diagnosis Rule | If 50g GLT is ≥200 mg/dL, GDM is diagnosed without Step 2 | N/A |
| Diagnostic Test | 100-gram oral Glucose Tolerance Test (OGTT) over 3 hours | 75-gram oral Glucose Tolerance Test (OGTT) over 2 hours |
| Diagnostic Thresholds | Carpenter-Coustan Criteria:<br>• Fasting: ≥95 mg/dL (5.3 mmol/L)<br>• 1-hour: ≥180 mg/dL (10.0 mmol/L)<br>• 2-hour: ≥155 mg/dL (8.6 mmol/L)<br>• 3-hour: ≥140 mg/dL (7.8 mmol/L) | IADPSG Criteria:<br>• Fasting: ≥92 mg/dL (5.1 mmol/L)<br>• 1-hour: ≥180 mg/dL (10.0 mmol/L)<br>• 2-hour: ≥153 mg/dL (8.5 mmol/L) |
| Criteria for Diagnosis | Two or more abnormal values (ACOG notes 1 abnormal value identifies an intermediate high-risk cohort) | One or more abnormal values |
| Clinical Impact | Lower overall diagnosis rate (~6%–9%), focusing on higher-risk clinical phenotypes | Higher diagnosis rate (~15%–20%), detecting milder degrees of glucose intolerance |
A 29-year-old G1P0 at 26 4/7 weeks gestation undergoes universal screening for gestational diabetes. Her non-fasting 50-gram 1-hour glucose challenge test result is 158 mg/dL. She subsequently completes a diagnostic 100-gram 3-hour oral glucose tolerance test with the following plasma glucose results: Fasting: 102 mg/dL; 1-hour: 188 mg/dL; 2-hour: 162 mg/dL; 3-hour: 132 mg/dL. Based on the Carpenter-Coustan diagnostic criteria, which diagnosis and initial management plan should the nurse-midwife establish?